These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 24449780

  • 1. Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
    Sader HS, Rhomberg PR, Jones RN.
    Antimicrob Agents Chemother; 2014; 58(4):2434-7. PubMed ID: 24449780
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [Abstract] [Full Text] [Related]

  • 3. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
    Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.
    Antimicrob Agents Chemother; 2016 Apr; 60(4):1967-73. PubMed ID: 26729494
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
    Vanscoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5924-30. PubMed ID: 24041895
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.
    Estabrook M, Bussell B, Clugston SL, Bush K.
    J Clin Microbiol; 2014 Nov; 52(11):4049-52. PubMed ID: 25143578
    [Abstract] [Full Text] [Related]

  • 6. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
    Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.
    Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
    VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2809-14. PubMed ID: 23629705
    [Abstract] [Full Text] [Related]

  • 8. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
    Melchers MJ, van Mil AC, Mouton JW.
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model.
    Melchers MJ, Mavridou E, van Mil AC, Lagarde C, Mouton JW.
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7272-7279. PubMed ID: 27671063
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC, Fiorenza MA, Estrada SJ.
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
    Horiyama T, Kanazawa S, Hara T, Izawa M, Sato T, Yamaguchi T, Tsuji M, Maki H.
    J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
    [Abstract] [Full Text] [Related]

  • 17. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A.
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I.
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.